IgE过敏血液检测市场：依检测类型、技术、应用、最终用户和通路划分－2026-2032年全球预测

2025 年 IgE 过敏血液检测市值为 331 亿美元，预计到 2026 年将成长至 347.9 亿美元，复合年增长率为 5.46%，到 ​​2032 年将达到 480.3 亿美元。

主要市场统计数据
基准年 2025	331亿美元
预计年份：2026年	347.9亿美元
预测年份 2032	480.3亿美元
复合年增长率 (%)	5.46%

权威概述了 IgE 过敏血液检测如何重新定义医疗保健环境中的诊断途径、检查室工作流程和临床决策。

IgE介导的过敏检测融合了临床需求和诊断技术创新，是准确识别引起阵发性和慢性过敏性疾病的致敏因素的基础。临床医生越来越多地利用血液IgE检测来补充病历和皮肤试验，尤其是在皮肤试验禁忌或多过敏原检测有助于明确诊断的情况下。随着诊疗路径向个体化方向发展，检查室和照护现场相关人员正在调整工作流程，将成分降解诊断和传统的特异性IgE检测相结合，并着重于临床效用和可重复性。

检测方法和诊断技术的快速成熟如何推动新的临床工作流程、检查室自动化和以患者为中心的过敏管理模式。

IgE过敏诊断领域正经历着一场变革，其驱动力来自于技术的成熟、临床需求的提升以及对个人化患者管理日益重视的。组成降解诊断技术的进步使得多过敏原检测成为可能，超越了单一过敏原的识别，能够揭示分子层面的致敏模式。这使得更精准的风险分层和更有针对性的规避策略成为可能。同时，包括全自动化学冷光免疫检测和高性能萤光酵素免疫分析法在内的检测平台的改进，在提高检查室通量的同时，也提升了分析的准确性。

我们将评估新贸易措施对整个检测生态系统的诊断供应链、采购实践和检查室韧性的营运和策略影响。

美国2025年实施的新关税措施，为诊断试剂生产商和检查室采购商的采购趋势和供应链策略带来了显着变化。由于零件和试剂高度依赖进口，进口压力迫使生产商加快审查筹资策略，重新评估供应商合同，并在某些情况下加快区域供应商的认证。这些营运变化已波及下游诊断检查室和医疗保健系统，促使他们重新评估采购週期、库存缓衝以及试剂供应合约的柔软性。

详细的细分资讯揭示了测试类型、检测技术、临床应用、最终用户环境和通路如何影响产品设计和采用。

对细分市场的深入分析揭示了每种检测类型、技术、应用、最终用户和分销管道的不同需求驱动因素和营运考虑。基于检测类型的差异包括成分特异性诊断、特异性IgE和总IgE检测。成分特异性诊断活动进一步细分为多过敏原检测（旨在优化致敏谱分析的广度）和单过敏原检测（旨在解决特定的临床问题）。特异性IgE检测区分成人和儿童应用场景，因为两者在检体处理和结果解读方面存在差异。总IgE检测服务提供定性快速检测和定量检测两种形式，后者能够反映潜在的免疫状态。这些检测类型的差异直接影响检查室工作流程、报告格式和临床医生培训需求。

区域诊断趋势表明，临床实践、法规环境和医疗保健基础设施如何决定不同全球医疗保健系统中检测方法的采用。

从区域观点来看，临床实践、法规结构和医疗基础设施相互作用，共同决定了IgE过敏诊断的推广应用路径。在美洲，完善的检测网路和强大的专科转诊途径促进了多成分过敏原诊断和高通量自动化平台的广泛应用。同时，私营和公共保险公司在报销谈判中优先考虑临床效用和诊断结果的清晰度。在欧洲、中东和非洲，不同的法规环境和多元化的医疗资金筹措模式要求采用灵活的分销策略和基于本地的临床检验。在这些市场，与当地检测机构和学术机构的合作能够加速临床医生对IgE诊断的接受度和实证医学证据的累积。在亚太地区，医院基础设施的快速发展、诊断检查室的扩建以及对儿童过敏治疗日益增长的关注，为定量总IgE检测法和特异性IgE检测创造了有利条件。然而，当地的生产和监管因素往往会影响采购选择。

竞争格局模式显示平台差异化、策略合作和卓越的服务品质如何推动诊断技术的应用和临床整合。

诊断公司之间的竞争主要集中在平台差异化、更广泛的检测组合以及旨在扩大临床应用范围的策略联盟。优先考虑互操作系统和全面检测项目的机构往往能够与检查室工作流程和临床医生决策过程深度整合。投资于检测标准化、外部品质保证和临床医生解读工具能够增强人们对检测结果的信心，并支持从过敏和免疫学到基层医疗等跨学科的临床应用。

产业领导者应关注的实际策略重点包括：供应链韧性、与临床医生的合作、模组化产品设计以及数据驱动的价值证明。

产业领导者应寻求供应链韧性、临床参与和产品多功能性之间的实质平衡，以保持竞争力并发挥临床意义。他们应优先选择关键试剂和组件的替代供应商，并尽可能探索区域性生产伙伴关係，以降低贸易引发的供应衝击风险。同时，他们应透过投资平台模组化设计来维持检查室客户的服务连续性，从而降低营运风险，使耗材能够在不影响分析完整性的前提下进行替换。

我们采用了一种严谨的混合调查方法，结合了对临床相关人员的访谈、对测试平台的技术审查以及基于场景的供应链分析，以获得可操作的见解。

本分析的研究基础是将对临床负责人、实验室经理和采购专家的访谈与对同行评审的临床文献、监管指导文件以及公开的检测平台技术规范的系统性回顾相结合。相关人员的定性意见体现在对临床应用障碍、操作限制和采购决策标准的解释。临床发现和技术文件的交叉检验证实，关于检测性能特征和实施实际情况的观察结果与临床实践和製造商规范均相符。

将诊断创新、操作要求和协作策略进行简洁整合，以将 IgE 检测的进步与改善患者照护联繫起来。

总而言之，IgE过敏血液检测的格局正在从分散的诊断方法转向以技术驱动的整合方法，从而支持个人化过敏治疗。可降解诊断技术和实验室自动化的进步使临床医生能够获得更清晰的免疫学特征，而检查室和采购团队则面临着维持服务连续性和成本效益的营运压力。贸易中断进一步加剧了对具有韧性的筹资策略和灵活产品设计的迫切需求，而监管环境和医疗服务提供方面的区域差异也要求采取因地制宜的方法。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依检测类型分類的IgE过敏血液检测市场

• 按组件进行诊断
  • 多过敏原检测
  • 单一过敏原
• 特异性IgE
  • 成人版
  • 适合儿童
• 总IgE
  • 定性
  • 定量

第九章：IgE过敏血液检测市场：依技术划分

• 化学冷光免疫检测
  • 全自动
  • 半自动
• 酵素免疫分析法
• 萤光酵素免疫分析法

第十章：IgE过敏血液检测市场：依应用领域划分

• 药物过敏
• 食物过敏
• 呼吸道过敏

第十一章：IgE过敏血液检测市场：以最终用户划分

• 诊所
• 诊断检查室
• 医院
• 研究机构

第十二章：IgE过敏血液检测市场：依通路划分

• 直销
• 批发商
• 线上销售

第十三章：IgE过敏血液检测市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 IgE过敏血液检测市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章：IgE过敏血液检测市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章：美国IgE过敏血液检测市场

第十七章：中国IgE过敏血液检测市场

第十八章 竞争情势

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• bioMerieux SA
• Danaher Corporation
• DST Diagnostische Systeme & Technologien GmbH
• Eurofins Scientific SE
• HYCOR Biomedical LLC
• Laboratory Corporation of America Holdings
• Omega Diagnostics Group PLC
• Quest Diagnostics Incorporated
• R-Biopharm AG
• Roche Holdings, Inc.
• Siemens Healthineers AG
• Stallergenes Greer plc
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.

The IgE Allergy Blood Tests Market was valued at USD 33.10 billion in 2025 and is projected to grow to USD 34.79 billion in 2026, with a CAGR of 5.46%, reaching USD 48.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 33.10 billion
Estimated Year [2026]	USD 34.79 billion
Forecast Year [2032]	USD 48.03 billion
CAGR (%)	5.46%

An authoritative overview of how IgE allergy blood testing is redefining diagnostic pathways, laboratory workflows, and clinical decision-making across care settings

IgE-mediated allergy testing sits at the intersection of clinical need and diagnostic innovation, serving as a cornerstone for precise identification of sensitizations that drive episodic and chronic allergic disease. Clinicians increasingly rely on blood-based IgE assessments to complement patient histories and skin testing, particularly when skin testing is contraindicated or when multi-allergen panels accelerate diagnostic clarity. As care pathways evolve toward greater personalization, laboratory and point-of-care stakeholders are adapting workflows to integrate both component resolved diagnostics and conventional specific IgE assays, with a focus on clinical utility and reproducibility.

Shifts in laboratory automation, assay sensitivity, and clinician demand are redefining how IgE testing is perceived within broader immunology and allergy management. Alongside these technical developments, payers and procurement teams are scrutinizing the value proposition of different test formats, balancing throughput, ease of interpretation, and the potential to reduce downstream clinical uncertainty. Consequently, organizations across healthcare delivery and diagnostics are reassessing investment priorities to ensure testing portfolios support both acute decision-making and long-term allergy management strategies.

How rapid technological maturation in assays and diagnostics is catalyzing new clinical workflows, laboratory automation, and patient-centered allergy management models

The landscape of IgE allergy diagnostics is undergoing transformative shifts driven by technological maturation, clinical expectation, and a heightened emphasis on personalized patient management. Advances in component resolved diagnostics have moved beyond single-allergen determination to offer multi-allergen panels that reveal molecular sensitization patterns, thereby enabling more nuanced risk stratification and targeted avoidance strategies. At the same time, improvements in assay platforms, including fully automated chemiluminescence immunoassays and high-performing fluorescence enzyme immunoassays, are increasing laboratory throughput while tightening analytical precision.

These technological advances are accompanied by evolving clinical workflows. Clinicians are integrating both specific IgE testing for adult and pediatric populations and total IgE measurements provided in qualitative and quantitative formats into diagnostic algorithms depending on clinical context. Moreover, the rise of integrated laboratory information systems and data analytics is facilitating longitudinal tracking of IgE profiles, which supports allergists and primary care physicians in monitoring disease progression and response to immunotherapies. Transitioning from traditional paradigms to these more integrated models requires coordinated change management across laboratories, clinicians, and procurement stakeholders to realize improved patient outcomes.

Assessing the operational and strategic ramifications of new trade measures on diagnostic supply chains, procurement behavior, and laboratory resiliency across the testing ecosystem

The introduction of new tariff measures in the United States during 2025 has introduced discernible shifts in procurement dynamics and supply chain strategies for diagnostic manufacturers and laboratory buyers. Import-dependent components and reagent imports have experienced cost pressures that compel manufacturers to revisit sourcing strategies, re-evaluate supplier contracts, and, in some instances, accelerate qualification of regional suppliers. These operational changes are filtering downstream to diagnostic laboratories and healthcare systems, prompting a reassessment of procurement windows, inventory buffers, and contractual flexibility in reagent supply commitments.

Beyond procurement and inventory tactics, the tariff environment has incentivized firms to explore local manufacturing partnerships and to prioritize modular assay designs that allow substitution of tariff-affected consumables. In parallel, distributors and channel partners have had to adapt pricing and logistics models to preserve service levels while managing margin compression. For clinicians and healthcare providers, the effect has been a heightened focus on test selection criteria that balance analytical performance with supply resiliency, urging greater collaboration between clinical decision-makers and laboratory procurement teams to ensure continuity of care despite evolving trade conditions.

Detailed segmentation intelligence revealing how test types, assay technologies, clinical applications, end-user environments, and distribution pathways shape product design and adoption

A nuanced view of segmentation reveals differentiated demand drivers and operational considerations across test types, technologies, applications, end users, and distribution channels. Based on test type, distinctions arise among component resolved diagnosis, specific IgE, and total IgE; component resolved diagnosis activity differentiates further between multi-allergen panel approaches that optimize breadth of sensitization profiling and single allergen assays that support focused clinical questions; specific IgE testing distinguishes adult and pediatric use cases with divergent specimen handling and interpretive needs; total IgE services are delivered in both qualitative rapid formats and quantitative assays that inform baseline immune status. These test-type distinctions directly influence laboratory workflows, reporting formats, and clinician education needs.

Based on technology, assay selection among chemiluminescence immunoassay, enzyme linked immunosorbent assay, and fluorescence enzyme immunoassay shapes automation potential and throughput. Within chemiluminescence immunoassays, the choice between fully automated and semi-automated platforms speaks to the trade-off between labor optimization and capital flexibility. Based on application, clinical demand is segmented into drug allergy, food allergy, and respiratory allergy, each creating specific test ordering patterns, interpretation complexity, and follow-up pathways. Based on end user, implementation realities differ across clinics, diagnostic laboratories, hospitals, and research institutes, with each setting bringing distinct quality control, staffing, and reporting requirements. Based on distribution channel, procurement and service models vary among direct sales relationships, distributor networks, and online sales platforms, affecting lead times, technical support availability, and pricing transparency. Taken together, these segmentation dimensions guide manufacturers and laboratory leaders in aligning product design, go-to-market models, and educational outreach to the precise needs of clinicians and institutional buyers.

Regional diagnostics dynamics showing how clinical practices, regulatory contexts, and healthcare infrastructure determine testing adoption across diverse global healthcare systems

Regional perspectives underscore that clinical practice, regulatory frameworks, and healthcare infrastructure converge to determine the adoption trajectory of IgE allergy diagnostics. In the Americas, established laboratory networks and strong specialist referral pathways support broad adoption of both multi-allergen component diagnosis and high-throughput automated platforms, while private and public payers emphasize clinical utility and diagnostic clarity in reimbursement conversations. In Europe, Middle East & Africa, diverse regulatory environments and heterogeneous healthcare funding models demand adaptable distribution strategies and localized clinical validation; in these markets, partnerships with regional laboratories and academic centers can accelerate clinician acceptance and evidence generation. In the Asia-Pacific region, rapid investment in hospital infrastructure, expanding diagnostic laboratories, and a growing emphasis on pediatric allergy care create fertile ground for both quantitative total IgE assays and specific IgE testing, though local manufacturing and regulatory considerations often influence procurement choices.

Across regions, the balance between centralized laboratory testing and near-patient solutions varies with healthcare delivery models and geographic access to specialist care. Consequently, manufacturers and clinical networks must calibrate training, technical support, and supply chain design to the realities of each region, ensuring that assay performance translates into actionable clinical insight regardless of local constraints.

Competitive landscape patterns illustrating how platform differentiation, strategic partnerships, and service excellence drive diagnostic adoption and clinical integration

Competitive behavior among diagnostic companies is centered on platform differentiation, assay portfolio breadth, and strategic partnerships that extend clinical reach. Organizations that prioritize interoperable systems and comprehensive panel offerings often gain deeper integration into laboratory workflows and clinician decision-support pathways. Investment in assay standardization, external quality assurance, and clinician-facing interpretive tools enhances confidence in test results and supports clinical adoption across specialties ranging from allergy and immunology to primary care.

Meanwhile, collaborations between diagnostics manufacturers and reagent suppliers, contract manufacturers, and academic centers are shaping the innovation pipeline. These alliances can shorten time-to-validation for new allergen components and support real-world evidence generation. Sales and distribution strategies are also evolving: direct sales relationships facilitate tailored implementation and training, whereas distributor networks and online channels expand reach into fragmented markets. Across the competitive landscape, the firms that combine robust analytical performance with practical service delivery and strong educational outreach are best positioned to support clinician needs and laboratory scalability.

Action-oriented strategic priorities for industry leaders focused on supply resilience, clinician engagement, modular product design, and data-driven value demonstration

Industry leaders should pursue a pragmatic combination of supply resilience, clinical engagement, and product versatility to remain competitive and clinically relevant. Prioritize qualification of alternative suppliers for critical reagents and components and explore regional manufacturing partnerships where feasible to reduce exposure to trade-driven supply shocks. Concurrently, invest in platform modularity that allows substitution of consumables without compromising analytical integrity, which preserves service continuity for laboratory clients and reduces operational risk.

Strengthening clinician engagement through targeted education on interpretive nuances of component resolved diagnostics and age-specific considerations for specific IgE testing will amplify clinical utility and appropriate test utilization. Additionally, align commercial models to the realities of end users by offering flexible service and training packages tailored to clinics, diagnostic laboratories, hospitals, and research institutes. Finally, enhance data capabilities to support longitudinal patient tracking and real-world evidence generation, enabling clearer demonstration of clinical impact to payers and institutional purchasers and supporting sustained integration into care pathways.

A rigorous mixed-methods research approach combining clinical stakeholder interviews, technical review of assay platforms, and scenario-based supply chain analysis to produce actionable insights

The research underpinning this analysis synthesizes primary interviews with clinical leaders, laboratory directors, and procurement specialists, together with a structured review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical specifications for assay platforms. Qualitative input from stakeholders informed interpretations of clinical adoption barriers, operational constraints, and procurement decision criteria. Cross-validation between clinical insights and technical documentation ensured that observations about assay performance characteristics and implementation realities are grounded in both real-world practice and manufacturer specifications.

Data collection emphasized transparency in source attribution and methodological rigor in synthesizing diverse evidence streams. The approach prioritized triangulation of stakeholder perspectives to mitigate single-source bias and incorporated pragmatic assessments of supply chain and regulatory drivers through scenario-based analysis. Where direct quantitative aggregation was inappropriate, the methodology focused on thematic synthesis to produce actionable insights that respect the complexity of clinical, laboratory, and commercial environments.

A concise synthesis of diagnostic innovation, operational imperatives, and collaborative strategies needed to translate IgE test advances into improved patient care

In sum, the IgE allergy blood testing landscape is moving from fragmented diagnostic practices toward more integrated, technology-enabled approaches that support personalized allergy care. Advances in component resolved diagnostics and assay automation are enabling clinicians to obtain clearer immunological profiles, while laboratories and procurement teams navigate operational pressures to maintain service continuity and cost-effectiveness. Trade-related disruptions have reinforced the need for resilient sourcing strategies and flexible product designs, and regional variations in regulatory and healthcare delivery contexts require tailored market approaches.

Looking ahead, stakeholders who align product development with clinical decision-making needs, invest in clinician education, and fortify supply chain flexibility will be best positioned to translate diagnostic innovation into improved patient management. Closing the gap between analytical capability and practical clinical implementation will rely on collaborative effort across manufacturers, laboratories, clinicians, and distributors to ensure testing reliably informs patient-centered care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IgE Allergy Blood Tests Market, by Test Type

• 8.1. Component Resolved Diagnosis
  • 8.1.1. Multi Allergen Panel
  • 8.1.2. Single Allergen
• 8.2. Specific Ige
  • 8.2.1. Adult
  • 8.2.2. Pediatric
• 8.3. Total Ige
  • 8.3.1. Qualitative
  • 8.3.2. Quantitative

9. IgE Allergy Blood Tests Market, by Technology

• 9.1. Chemiluminescence Immunoassay
  • 9.1.1. Fully Automated
  • 9.1.2. Semi Automated
• 9.2. Enzyme Linked Immunosorbent Assay
• 9.3. Fluorescence Enzyme Immunoassay

10. IgE Allergy Blood Tests Market, by Application

• 10.1. Drug Allergy
• 10.2. Food Allergy
• 10.3. Respiratory Allergy

11. IgE Allergy Blood Tests Market, by End User

• 11.1. Clinics
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals
• 11.4. Research Institutes

12. IgE Allergy Blood Tests Market, by Distribution Channel

• 12.1. Direct Sales
• 12.2. Distributors
• 12.3. Online Sales

13. IgE Allergy Blood Tests Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. IgE Allergy Blood Tests Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. IgE Allergy Blood Tests Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States IgE Allergy Blood Tests Market

17. China IgE Allergy Blood Tests Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Abbott Laboratories
• 18.6. Becton, Dickinson and Company
• 18.7. Bio-Rad Laboratories, Inc.
• 18.8. Bio-Techne Corporation
• 18.9. bioMerieux SA
• 18.10. Danaher Corporation
• 18.11. DST Diagnostische Systeme & Technologien GmbH
• 18.12. Eurofins Scientific SE
• 18.13. HYCOR Biomedical LLC
• 18.14. Laboratory Corporation of America Holdings
• 18.15. Omega Diagnostics Group PLC
• 18.16. Quest Diagnostics Incorporated
• 18.17. R-Biopharm AG
• 18.18. Roche Holdings, Inc.
• 18.19. Siemens Healthineers AG
• 18.20. Stallergenes Greer plc
• 18.21. Sysmex Corporation
• 18.22. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL IGE ALLERGY BLOOD TESTS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY MULTI ALLERGEN PANEL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY MULTI ALLERGEN PANEL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY MULTI ALLERGEN PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SINGLE ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SINGLE ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SINGLE ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FULLY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FULLY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FULLY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SEMI AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SEMI AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SEMI AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FLUORESCENCE ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FLUORESCENCE ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FLUORESCENCE ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DRUG ALLERGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DRUG ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DRUG ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FOOD ALLERGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FOOD ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FOOD ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESPIRATORY ALLERGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESPIRATORY ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESPIRATORY ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 85. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 86. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 90. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 91. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 92. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 93. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 94. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 95. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 96. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 101. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 102. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 103. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 104. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 105. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 106. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 110. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 111. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 112. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 113. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 128. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 129. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 130. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 131. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 132. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 133. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 134. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 136. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 137. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 138. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 139. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 140. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 141. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 142. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 143. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 144. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 145. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 146. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 147. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 148. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 149. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 150. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 151. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 152. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 153. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 154. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 155. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 156. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 157. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 158. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 159. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 160. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 161. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 162. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 163. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 164. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 165. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 166. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 167. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 168. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 169. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 170. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 171. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 172. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 173. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 174. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 175. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 176. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 177. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 178. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 179. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 180. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 181. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 182. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 183. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 184. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 185. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 186. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 187. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 188. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 189. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 190. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 191. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 192. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 193. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 194. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 195. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 196. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 197. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 198. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 199. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 200. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 201. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 202. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 203. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 204. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 205. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 206. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 207. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 208. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 209. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 210. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 211. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 212. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 213. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 214. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 215. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 216. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 217. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 218. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 219. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 220. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 221. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 222. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 223. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 224. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 225. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 226. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 227. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 228. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 229. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 230. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 231. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 232. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 233. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 234. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 235. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 236. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 237. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 238. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
• TABLE 239. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
• TABLE 240. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
• TABLE 241. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 242. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
• TABLE 243. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 244. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 245. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)